‘This year’s grants plan marks a substantial milestone as we will have surpassed $10 million in research funding since the program’s inception in 2003,’ stated Julie Fleshman, president and CEO of the Pancreatic Cancer Actions Network. ‘During this time period, we have begun to create a community of researchers dedicated to making progress in the fight pancreatic cancer. For so many years, the pancreatic cancer study community was sparse and underfunded. We are beginning to see a transformation, due in part, to your advocacy and research initiatives.’ ‘All cancers are in great need of further investigation and increased funding, but due to its low survival price, pancreatic cancer is difficult and us with an urgent call to action particularly,’ said Margaret Foti, Ph.D., M.D.The superiority of nintedanib over placebo with regards to the primary and key secondary end points was tested with the use of a hierarchical procedure to take into account multiple comparisons . Sensitivity analyses were performed to measure the robustness of the full total results for the primary and key secondary end points. Multiple imputation sensitivity analyses were performed to assess the effect of missing data and offer estimates of the treatment impact under different assumptions about missing data .